When a long-dormant office park finally gets an occupants, that’s one sign of good news after a long recession. Another sign is news from the architecture sector — which contracted dramatically after the 2008 financial meltdown — that at least one company is hiring again and is bullish on the future.
“The architecture industry is seeing a resurgence in activity as businesses, schools and universities dust off plans to build post the economic downturn,” says a spokesperson for KSS Architects at 337 Witherspoon Street in Princeton and with another office in Philadelphia. The firm began 2013 with 11 new hires, five in the Princeton office.
In an E-mail exchange KSS partner Edmund Klimek said that “KSS has experienced an expansion of business in response to what we think is the re-emergence of growth in construction and development. This re-emergence is fueled by pent-up demand, active engagement by state government to promote growth, and an overall turnaround in the market. We’re seeing this across a wide range of clients — across education, industrial, and commercial clients.”
KSS designed the recently opened headquarters facility for Bracco Diagnostics at the Matrix Corporate Campus in Monroe. “After acquiring the former Rhodia Pharmaceutical Campus,” said Klimek, “Matrix teamed up with KSS to re-imagine the unattractive 1970s laboratory and office complex. Bracco now occupies one of the most visible buildings from the New Jersey Turnpike.”
Responding to what is considered a new demand by information age workers, the Bracco facility boasts an “open office” design.
KSS also designed Amerihealth’s new office in the Matrix Corporate Campus and is working to transform additional buildings into cafe and office space.
Among other projects underway, the firm is designing a new corporate headquarters for Burlington Coat Factory in Burlington. “Encouraged by smart growth incentives from the state, this project also responds to changes in workplace expectations and will be a true representation of Burlington’s brand,” said Klimek.
The key to the firm’s ability to sustain itself through the recession? According to Klimek, “we stayed engaged with our clients, helping position them to be in the right place when the economy turned around. We diligently worked on all things great and small. By keeping a close pulse on the changes occurring in the marketplace, we quickly responded to the altered demand and gained an inside look at what new buildings would be in the new economy — more sustainable, more quality, more responsive to changes in the demographics of the workplace.”
Quantex Laboratories, 3000 Eastpark Boulevard, Suite 100, Cranbury 08512; 609-655-4047; fax, 609-655-4374. James Menoutis, CEO. www.quantexlabs.com.
Quantex Laboratories Inc., a contract analytical services company, has moved its analytical testing laboratory to 3000 Eastpark Boulevard in Cranbury.
The new facility is nearly four times the size of Quantex’s previous site in Edison, according to a news release. The company, which provides analytical, research, and consulting services in the chemical sciences, plans to add microbiological testing capabilities later in the year to the lab.
“The new facility enables us to offer our clients a broader range of fully compliant services,” said James Menoutis, president and CEO of Quantex. “We’ve also made a significant investment in upgrading our instrumentation to service the growing needs of the bio/pharmaceutical, personal care products, and cosmetics markets with expanded capabilities.”
Menoutis said that the planned expansion was moved forward after the company’s previous location sustained damage from Hurricane Sandy. Quantex is located in the former Pharmacopeia Drug Development headquarters, space previously leased by Ligand Pharmaceuticals, which relocated its operations to California last year.
“One of the factors in our consideration to remain in New Jersey was the ability to hire skilled laboratory professionals,” said Menoutis. “We believe that our presence helps retain and grow the science and research communities in the state.”
Last year Quantex received two CRO Leadership Awards in the areas of productivity and regulatory compliance. The awards were based on the opinions of more than 40,000 pharmaceutical and biopharmaceutical executives who were invited to participate in a survey of the CRO industry.
“We consider ourselves as partners in meeting the standards and goals set by our clients and regulators in achieving high marks for compliance,” said Menoutis. “As partners with our clients, our focus on productivity moves projects from concept to market, helping clients achieve developmental and marketing milestones in a timely and cost-effective manner.”
Shiseido America Inc., 366 Princeton-Hightstown Road, East Windsor 08520; 609-371-5800; fax, 609-371-8170. Tamaki Shimamoto, president and CEO. www.us.shiseido.com.
Shiseido America, a manufacturer of personal care products and pharmaceuticals, is planning to add 72,988 square feet to the company’s 211,000-square-foot facility on Princeton-Hightstown Road in East Windsor. The expansion is projected to add 10 fulltime employees to Shiseido’s current staff of 150.
The project’s first phase involves a 54,580-square-foot office addition to the existing warehouse building that will include additional parking, a storm water management basin, a widened driveway, and an expanded loading area. Phase two is an 18,408-square-foot addition behind the existing office building.
Officials say the expansion will enable the company to gradually move distribution from its facility in Oakland to East Windsor. The warehouse and manufacturing additions will increase space for the handling of the company’s cosmetics brands, which include Shiseido, NARS, and Bare Escentuals. It will also increase distribution capabilities on site to more efficiently handle the export of products manufactured at the East Windsor facility to Europe and Asia. Shiseido anticipates completion of work by mid-summer.
“East Windsor’s strategic location also provides easy access to major piers, airports and highways, enabling our company to efficiently distribute products domestically and internationally,” said Edward Houlihan, Shiseido America president and COO.
Shiseido America, a subsidiary of the Japanese-based corporation Shiseido Company, established operations in East Windsor in 1998 and serves as a manufacturing center for the company.
PendoTECH, 3490 Route 1 North, Suite 15F, Princeton 08540; 609-802-1262; fax, 609-784-7889. Jim Furey, general manager. www.pendotech.com.
PendoTECH, a designer of products to optimize the bioprocess, has relocated its regional headquarters to a larger office in the Princeton Service Center at 3490 Route 1 North.
PendoTECH owner and president James Furey said the new office allows the company to remain in close proximity to “some of the biggest pharmaceutical companies in the country and in the heart of the state-designated industry cluster known as Einstein’s Alley”
According to Furey, there was a need for a larger office due to a steady increase in product demands. “The new office includes upgraded amenities such as client meeting rooms, expanded reception area, product showroom, a state-of-the-art laboratory, and space for future growth. The move will enable greater access to our current and emerging clients,” Furey said.
A pioneer in the area of in-line, low cost sensory technology, PendoTECH products are used for enhancing the production process for biopharmaceuticals such as antibodies, recombinant proteins, vaccines, gene therapy and cell therapy products.
The high tech, low cost in-line process sensors are designed for single use or limited use in the biotech industry where a compact design, accuracy, and high level of cleanliness is required. PendoTECH manufactures the related electronic instruments to read the sensors and also serve as transmitters. Depending on customer requirements, integrated process control systems are designed and manufactured for monitoring and control of an entire process.
Furey, who founded the company in 2005, grew up in north Philadelphia, the son of a banker, and majored in chemical engineering, Class of 1988, at Drexel University. He worked at National Starch & Chemical in Bridgewater while earning a Rutgers MBA, and focused on international business. “I always knew I wanted to go into the business end of engineering,” he says. When he took a job with Millepoure he was transferred to Boston, where he met Dennis Annarelli, an MIT PhD who is now the technical manager of Pendotech.
“We started the company with help on product design from Henry Wieck at Polygenesis,” says Furey. “We both do the design on paper, Polygenesis does the manufacturing, and we do the testing.”
Tris Pharma, 2033 Route 130 South, Brunswick Business Park, Suite D, Monmouth Junction 08852; 732-940-2800; fax, 732-940-2855. Ketan Mehta, president. www.trispharma.com.
Tris Pharma Inc. recently purchased the flex building at 110 Melrich Road in Cranbury from Matrix Company for $4.24 million.
The 117,600-square-foot industrial building, which was constructed in 1986, is located in the South Brunswick Industrial Park. David Zimmel of Zimmel Associates Inc. represented both Matrix and TrisPharma in the deal.
In addition to manufacturing generics, Tris also focuses on researching and developing drug delivery technologies.
Orthobond, 675 Route 1 South, Technology Center of New Jersey, North Brunswick 08902; 732-729-6235; fax, 732-745-7470. Marc Burel, general manager, business development. www.orthobond.com.
Orthobond Corporation, the largest tenant at the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick, was one of 65 companies receiving a share of $60 million in funding from the state’s Technology Business Tax Certificate Transfer Program this year.
Orthobond was founded in 2003 with the goal of producing safe and effective bio-interfaces for current and future generation medical devices that will ultimately lead to improvements in patients’ health and lifestyle.
Since moving to CCIT in 2009, the company has grown from two to four laboratories and expanded from a staff of three to eleven, creating six new jobs over the past two years alone.
Orthobond Chief Operating Officer Marc Burel noted that emerging biotechnology companies in particular require a lot of support to bring products to market. “As a growing biotechnology business, the ability to sell losses for cash through the Technology Business Tax Certificate Transfer program has been critical to keeping us on track during these early years,” Burel said.
“Our location at CCIT has also provided us with a host of resources essential to a young company’s growth, including the opportunity to interact with our neighbors, share instrumentation, discuss technology and network,” Burel said.
CCIT is part of the Technology Center of New Jersey, which sits on more than 50 acres in North Brunswick. CCIT, the state’s leading life sciences incubator, has added 14 new tenants since 2010, including Linnovision Inc., which moved to the center in February. CCIT has helped support the creation of an estimated 1,000 new jobs in the state.
Other Mercer County companies awarded funding from the grant include Voxware, 200 American Metro Boulevard; Princeton Optronics, 1 Electronics Drive; Ocean Power Technologies, 1590 Reed Road; Advaxis, 305 College Road East; Agennix USA, 101 College Road East; IntegriChain, 100 Canal Pointe Boulevard; SightLogix, 745 Alexander Road; Soligenix, 29 Emmons Drive; and Alphion Corporation, 196 Princeton-Hightstown Road.
Middlesex companies receiving funding include Amicus Therapeutics, 1 Cedar Brook Drive; Blacklight Power, 493 Old Trenton Road; Palatin Technologies, 4 Cedar Brook Drive, Princeton Lightwave, 2555 Route 130 South; Replication Medical, 7 Clarke Drive; Vaxinnate Corporation, 3 Cedar Brook Drive; Argyle Therapeutics, 7 Deer Park Drive; CytoSorbents, 7 Deer Park Drive; Insmed, 9 Deer Park Drive; Rive Technology, 1 Deer Park Drive; Signum Biosciences, 7 Deer Park Drive; TyRx Pharma, 1 Deer Park Drive; and Liquid Light, 11 Deer Park Drive.